LoL skins 2025 are finally here, and Riot Games has packed an exciting lineup for all players. These include returning favorites like Cafe Cuties and exciting new themes, like the Masque of the Black ...

Healthcare & Pharmaceuticalscategory Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO January 27, 2025 The German economy is in deep crisis, with gross domestic ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9. Discover outperforming stocks and invest smarter with Top Smart Score ...

Lyndra’s drug delivery platform optimises the delivery of oral medicines. Credit: Stock-Asso/Shutterstock. Lyndra Therapeutics and Thermo Fisher Scientific have entered a strategic partnership to ...

The new season has finally hit the live servers and we have already started seeing major shifts in the meta. With the introduction of Feats of Strength and the new epic monster Atakhan, the game feels ...

Getting new players interested is a necessary part of keeping LoL alive and thriving for years to come. Maddy Marquissee, growth lead for League of Legends, represents that team and is open about ...

Like every new season in League of Legends, Riot Games has completely thrown the meta on its head with season 15. Patch 25.S1.2 aims to balance some of the more drastic changes made at the start ...

If this has you inspired to jump back in, have a look at our LoL tier list and our guide to what League of Legends skins are currently on sale. You can also follow us on Google News for daily PC ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to back-to-back series from obesity-focused Metsera that totaled more than $500M in a ...

Other newcomers to the weight-loss drug field include Kailera Therapeutics, which launched in October with $400 million in funding, and Metsera, which debuted in April with $290 million and has ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has filed for a $100M initial public offering. While the company didn't specify terms in its SEC filing ...

This $442 million deal significantly boosted Sage's stock value in post-trading. In financial developments, Metsera, a weight-loss drug developer, reported a widened loss in its U.S. IPO filing, ...